- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02293954 | Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer | active not recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06088472 | TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors | active not recruiting | Phase 1 | 12 | Grit BiotechnologyINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02974738 |
| A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) |
| active not recruiting |
| Phase 1 |
| 120 |
| Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY |
| 0 |
| Sep 16, 2026 |
| clinicaltrials |
| NCT01375829 | Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04739696 | Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.(eCare) | active not recruiting | N/A | 538 | University of Colorado, DenverOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT00878163 | GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04243499 | First-in-Human Study of ICT01 in Patients With Advanced Cancer(EVICTION) | active not recruiting | Phase 1 / Phase 2 | 293 | ImCheck Therapeutics, an Ipsen companyINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06507306 | A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | active not recruiting | Phase 1 | 92 | Kumquat Biosciences Inc.INDUSTRY | 4 | Sep 2, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04725474 | First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)(GDFATHER) | active not recruiting | Phase 1 / Phase 2 | 199 | CatalYm GmbHINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT04928508 | Advanced or Recurrent Solid Tumors Treated With SHetA2(Okgyn1) | active not recruiting | Phase 1 | 50 | University of OklahomaOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT00045201 | Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT00935090 | 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer | active not recruiting | — | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06380660 | Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 298 | Acerand Therapeutics (Shanghai) LimitedINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04130516 | Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | active not recruiting | Phase 1 / Phase 2 | 200 | Linnaeus Therapeutics, Inc.INDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT02112565 | RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists | active not recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04328844 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | active not recruiting | Phase 1 | 210 | iOncturaINDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT05887492 | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 126 | Tango Therapeutics, Inc.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04673942 | A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors(BETA-PRIME) | active not recruiting | Phase 2 | 140 | EpicentRx, Inc.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06104488 | A Study of Avutometinib for People With Solid Tumor Cancers | active not recruiting | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05678010 | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer | active not recruiting | Phase 1 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05359445 | IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor | active not recruiting | Phase 1 | 95 | Immatics Biotechnologies GmbHINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT01281176 | High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05071846 | MVX-ONCO-2 in Advanced Solid Tumors | active not recruiting | Phase 1 | 6 | University Hospital, GenevaOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT00477958 | Assessment Tool for Older Patients With Cancer | active not recruiting | N/A | 1,062 | City of Hope Medical CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07137195 | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) | active not recruiting | N/A | 47 | Ion Beam ApplicationsINDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04041310 | Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 115 | Nouscom SRLINDUSTRY | 6 | Feb 13, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07153094 | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen) | active not recruiting | N/A | 47 | Ion Beam ApplicationsINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301) | active not recruiting | Phase 1 / Phase 2 | 310 | Tyra Biosciences, IncINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT07152353 | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan) | active not recruiting | N/A | 47 | Ion Beam ApplicationsINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05631899 | CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors | active not recruiting | Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT01843413 | Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases | active not recruiting | Phase 1 | 33 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05354323 | NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors | active not recruiting | Phase 1 | 6 | NEC OncoImmunity ASINDUSTRY | 1 | Jun 26, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 56 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04643574 | NeoTIL in Advanced Solid Tumors | active not recruiting | Phase 1 | 42 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05662397 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | active not recruiting | Phase 1 / Phase 2 | 77 | HotSpot Therapeutics, IncINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT06026254 | A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial | active not recruiting | Phase 1 | 2 | ImmuneSensor Therapeutics Inc.INDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials